BR112021005702A8 - Método para selecionar neoepítopos - Google Patents

Método para selecionar neoepítopos

Info

Publication number
BR112021005702A8
BR112021005702A8 BR112021005702A BR112021005702A BR112021005702A8 BR 112021005702 A8 BR112021005702 A8 BR 112021005702A8 BR 112021005702 A BR112021005702 A BR 112021005702A BR 112021005702 A BR112021005702 A BR 112021005702A BR 112021005702 A8 BR112021005702 A8 BR 112021005702A8
Authority
BR
Brazil
Prior art keywords
selecting
neoepitopes
mhc
selecting neoepitopes
classifying
Prior art date
Application number
BR112021005702A
Other languages
English (en)
Other versions
BR112021005702A2 (pt
Inventor
Monika Sekelja
Karoline Schjetne
Agnete Brunsvik Fredriksen
Original Assignee
Vaccibody As
Nykode Therapeutics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccibody As, Nykode Therapeutics AS filed Critical Vaccibody As
Publication of BR112021005702A2 publication Critical patent/BR112021005702A2/pt
Publication of BR112021005702A8 publication Critical patent/BR112021005702A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Oncology (AREA)
  • Theoretical Computer Science (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MÉTODO PARA SELECIONAR NEOEPÍTOPOS. para um indivíduo, selecionando neoepítopos de ligação ao MHC I e/ou MHC II e classificando-os com relação a suas utilidades clínicas. A presente invenção também fornece vacinas contra câncer obtidas pelos métodos conforme descrito neste documento.
BR112021005702A 2018-09-27 2019-09-27 Método para selecionar neoepítopos BR112021005702A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18197172 2018-09-27
EP18197172.2 2018-09-27
PCT/EP2019/076210 WO2020065023A1 (en) 2018-09-27 2019-09-27 Method for selecting neoepitopes

Publications (2)

Publication Number Publication Date
BR112021005702A2 BR112021005702A2 (pt) 2021-06-22
BR112021005702A8 true BR112021005702A8 (pt) 2022-11-08

Family

ID=63794302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021005702A BR112021005702A8 (pt) 2018-09-27 2019-09-27 Método para selecionar neoepítopos

Country Status (12)

Country Link
US (1) US20210388438A1 (pt)
EP (1) EP3856957A1 (pt)
JP (1) JP2022502416A (pt)
KR (1) KR20210065171A (pt)
CN (1) CN112771214A (pt)
AU (1) AU2019346023A1 (pt)
BR (1) BR112021005702A8 (pt)
CA (1) CA3111903A1 (pt)
IL (1) IL281771A (pt)
MX (1) MX2021003654A (pt)
SG (1) SG11202101965QA (pt)
WO (1) WO2020065023A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
BR112023019610A2 (pt) 2021-03-26 2023-12-12 Genentech Inc Método para tratar um sujeito com câncer, e, kit
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
KR20240019135A (ko) 2021-05-10 2024-02-14 니코데 테라퓨틱스 에이에스에이 작제물과 면역자극 화합물의 공동발현
WO2023244997A1 (en) * 2022-06-13 2023-12-21 The University Of North Carolina At Chapel Hill Compositions and methods for inducing anticancer immunity
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
SG10201912485PA (en) * 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
US10563266B2 (en) * 2015-07-14 2020-02-18 Personal Genome Diagnostics Inc. Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency
US20200232040A1 (en) * 2017-01-18 2020-07-23 Vinod P. Balachandran Neoantigens and uses thereof for treating cancer

Also Published As

Publication number Publication date
AU2019346023A1 (en) 2021-03-25
KR20210065171A (ko) 2021-06-03
BR112021005702A2 (pt) 2021-06-22
US20210388438A1 (en) 2021-12-16
MX2021003654A (es) 2021-05-28
IL281771A (en) 2021-05-31
CA3111903A1 (en) 2020-04-02
SG11202101965QA (en) 2021-04-29
EP3856957A1 (en) 2021-08-04
JP2022502416A (ja) 2022-01-11
WO2020065023A1 (en) 2020-04-02
CN112771214A (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
BR112021005702A8 (pt) Método para selecionar neoepítopos
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
EP4219559A3 (en) Antibodies for lilrb2
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
AU2015347015A8 (en) Antibody drug conjugates
CU20160101A7 (es) Inmunoglobulina con fab en tándem
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12016501366A1 (en) Novel anti-baff antibodies
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
TW201613643A (en) Anti-CDH6 antibody drug conjugates
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
AU2015249633A8 (en) Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
BR112017022022A2 (pt) arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas)
MX2021003180A (es) Métodos y kits para preparar sangre entera con inactivación de patógenos.
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
PE20180219A1 (es) Procesos para preparar fluorocetolidos
EA201990720A1 (ru) Способы детекции нейтрализующих антител к лептину
EA201891419A1 (ru) Пептид-олигонуклеотидные конъюгаты

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NYKODE THERAPEUTICS AS (NO)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]